Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02952001) was an extension study that followed on from an earlier trial involving people with uveitis — an inflammatory condition affecting the eye. A total of 28 people continued in the group that had received a 4 mg injection of CLS-TA (delivered into a specific layer at the back of the eye called the suprachoroidal space), while 5 people continued in the group that had received a sham (dummy) procedure. The study was measuring how long it took before participants needed additional treatment for their uveitis, as well as tracking changes in eye swelling, vision, and any adverse (unwanted) events. The reported data shows that the median time before additional uveitis treatment was needed was 344 days for the injection group and 332 days for the sham group. For eye swelling — measured as the thickness of a small central area of the retina — the injection group showed an average reduction of 174.5 microns (a unit of measurement smaller than a millimetre) from their starting point, while the sham group showed an average increase of 19.5 microns. For vision, measured by the number of letters read correctly on a standard eye chart, the injection group showed an average improvement of 12.1 letters and the sham group showed an average improvement of 14.0 letters. Regarding adverse events, 16 out of 28 participants in the injection group and 3 out of 5 in the sham group reported at least one treatment-emergent adverse event; serious adverse events were reported by 1 participant in the injection group and 0 in the sham group. No further detail about the nature of those events was included in the reported data. It is worth noting that the numbers of participants in this study — particularly in the sham group — were quite small, and a notable proportion of participants did not complete the study (14 in the injection group and 3 in the sham group). These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 36787524) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must already be taking part in a related study called CLS1001-301 and have completed it up to Visit 8 (the 6-month point)
- You must be willing and able to sign a consent form and agree to follow the study instructions and attend all required appointments
Who may not be able to join:
- You have received any additional treatments for uveitis (an eye inflammation condition) or taken any medications that are not allowed during the study
- At the time of joining this study, you currently need additional treatments for uveitis or are taking any medications that are not permitted
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Time to Additional Therapy for Uveitis
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.